Paul D Davis

This inventor holds 6 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Quanta Biodesign, Ltd., Eqip, LLC, Equip, LLC. Active years: 2002-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul D Davis. Retrieved from https://idiyas.com/inventor/paul-d-davis-4be0solh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 1.8

ph-index = 2

Forward Citations = 42(Granted Patents)

Company Filing History:

3 out of 3

Quanta Biodesign, Ltd.

Pierce Chemical Company

patents

5. 1 out of 2,172

University of Washington

patents

where one patent can have more than one assignee

Years Active: 2002-2022

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11510994 - Linkers for improving the stability of bioconjugates and the selectivity of payload release (2022-11-29),

2. 11505525 - Branched discrete PEG constructs (2022-11-22),

3. 10786497 - Discrete PEG constructs (2020-09-29),

4. 8637711 - Selective and specific preparation of discrete PEG compounds (2014-01-28),

5. 7888536 - Selective and specific preparation of discrete PEG compounds (2011-02-15),

6. 6432662 - Assay of peroxidase activity (2002-08-13),

Title: Paul D Davis: Innovator in Bioconjugate Technology

Introduction

Paul D Davis is a notable inventor based in Dublin, OH (US), recognized for his contributions to bioconjugate technology. He holds a total of six patents, showcasing his innovative approach to improving the stability and selectivity of payload release in bioconjugates.

Latest Patents

Among his latest patents, Davis has developed linkers designed to enhance the stability of bioconjugates and improve the selectivity of payload release. These linkers are engineered to minimize off-target payload release, particularly by extracellular cathepsins, and are applicable to antibody fragments that lack the steric protection of full antibodies. Additionally, these linkers are expected to facilitate more selective intracellular payload release, thereby improving the overall efficacy and safety of therapeutic applications. Another significant patent involves branched discrete polyethylene glycol constructs, which are versatile in attaching to various biologically active groups. These constructs are useful in diagnostics, therapeutics, and theranostics, providing a platform for innovative medical applications.

Career Highlights

Davis has worked with several prominent companies in the biotechnology field, including Quanta Biodesign, Ltd. and Pierce Chemical Company. His experience in these organizations has contributed to his expertise in bioconjugate technology and its applications in medicine.

Collaborations

Davis has collaborated with notable professionals in his field, including Edward C Crapps and Kelli D Feather-Henigan. These collaborations have further enriched his work and contributed to advancements in bioconjugate research.

Conclusion

Paul D Davis stands out as an influential inventor in the realm of bioconjugate technology, with a focus on enhancing the efficacy and safety of therapeutic applications. His innovative patents and collaborations reflect his commitment to advancing medical science.

Profile summary based on public USPTO records.